Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Neoplasma Vol.60, No.2, p.129-134, 2013 |
||
Title: Second line treatment in advanced non-small cell lung cancer (NSCLC): Comparison of efficacy of Erlotinib and chemotherapy | ||
Author: O. FIALA, M. PESEK, J. FINEK, J. KREJCI, Z. BORTLICEK, L. BENESOVA, M. MINARIK | ||
Abstract: Molecular targeted therapy based on tyrosine kinase inhibitors, directed at the epidermal growth factor receptor (EGFR) is one of novel options for management of NSCLC. Erlotinib is EGFR tyrosine kinase inhibitor used for treatment of the advanced NSCLC. This presented study is focused on comparison of erlotinib and chemotherapy efficacy in the second line treatment of the advanced NSCLC. DCR and PFS became the primary endpoints. DCR in patients treated with chemotherapy was 54.0% vs. 51.3% in patients without EGFR mutation treated with erlotinib (p=0.707); in patients harboring EGFR mutation, treated with erlotinib (n=9) outstanding results were achieved: 4 CR, 2 PR and 3 SD (not tested). Median of PFS in patients treated with chemotherapy was 2.1 months vs. 1.9 months in patients without EGFR mutation (p=0.879) vs. 8.4 months in patients harboring EGFR mutation treated with erlotinib (p=0.017). |
||
Keywords: EGFR-TKI, NSCLC, erlotinib, targeted treatment of NSCLC | ||
Published online: 26-Nov-2012 | ||
Year: 2013, Volume: 60, Issue: 2 | Page From: 129, Page To: 134 | |
doi:10.4149/neo_2013_017 |
||
|
download file |
|